Dopaminergic influences on emotional decision making in euthymic bipolar patients

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 274-282

  Burdick, Katherine E ^a   Braga, Raphael J ^b,c,d   Gopin, Chaya B ^e   Malhotra, Anil K ^b,c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bipolar disorder; decision making; dopamine; pramipexole

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL ARTICLE; DECISION MAKING; DOPAMINERGIC ACTIVITY; DRUG MEGADOSE; EMOTION; EXPECTANCY; FEMALE; GAMBLING; HUMAN; LEARNING; LEARNING DISORDER; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REWARD; TASK PERFORMANCE; TREATMENT DURATION;

ADULT; BIPOLAR DISORDER; DECISION MAKING; DOPAMINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE;

EID: 84890550336     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.177     Document Type: Article

References (61)

1. Adida M, Clark L, Pomietto P, Kaladjian A, Besnier N, Azorin JM et al (2008). Lack of insight may predict impaired decision making in manic patients. Bipolar Disord 10: 829-837.
2. Adida M, Jollant F, Clark L, Besnier N, Guillaume S, Kaladjian A et al (2011). Trait-related decision-making impairment in the three phases of bipolar disorder. Biol Psychiatry 70: 357-365.
3. Aiken CB (2007). Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 68: 1230-1236.
4. Altman EG, Hedeker DR, Janicak PG, Peterson JL, Davis JM (1994). The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry 36: 124-134.
5. Antonini A, Calandrella D (2011). Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol 7: 1307-1314.
6. Badre D (2012). Opening the gate to working memory. Proc Natl Acad Sci USA 109: 19878-19879.
7. Balleine BW, Delgado MR, Hikosaka O (2007). The role of the dorsal striatum in reward and decision-making. J Neurosci 27: 8161-8165.
8. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O et al (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised double-blind, placebo-controlled trial. Lancet Neurol 9: 573-580.
9. Bechara A, Damasio AR, Damasio H, Anderson SW (1994). Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50: 7-15.
10. Bechara A, Tranel D, Damasio H (2000). Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 123: 2189-2202.
11. Beninger RJ, Banasikowski TJ (2008). Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor. Neurotox Res 14: 57-70.
12. Berridge KC (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191: 391-431.
13. Bodi N, Keri S, Nagy H, Moustafa A, Myers CE, Daw N et al (2009). Reward-learning and the novelty-seeking personality: a betweenand within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 132: 2385-2395.
14. Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK (2012). Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 73: 103-112.
15. Busemeyer JR, Stout JC (2002). A contribution of cognitive decision models to clinical assessment: decomposing performance on the Bechara gambling task. Psychol Assess 14: 253-262.
16. Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF (1995). Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci Lett 196: 97-100.
17. Cardoso OC, Carvalho JCN, Cotrena C, Schneider-Bakos DG Kristensen HC, Fonseca RP (2010). Estudo de fidedignidade do instrumento neuropsicoló gico Iowa Gambling Task. Jornal Brasileiro de Psiquiatria 59: 279-285.
18. Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A et al (2004). Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 20: 131-138.
19. Chandler RA, Wakeley J, Goodwin GM, Rogers RD (2009). Altered risk-aversion and risk-seeking behavior in bipolar disorder. Biol Psychiatry 66: 840-846.
20. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA (2009). Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47: 1374-1381.
21. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62: 1377-1381.
22. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN Parish J et al (2007). Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30: 249-255.
23. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T Riederer P (2003). Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110: 1119-1127.
24. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000). Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68: 423-428.
25. Goldberg JF, Burdick KE, Endick CJ (2004). Preliminary randomized double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161: 564-566.
26. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ Robbins TW (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20: 1208-1215.
27. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
28. Johnson SL, Edge MD, Holmes MK, Carver CS (2012). The behavioral activation system and mania. Annu Rev Clin Psychol 8: 243-267.
29. Jollant F, Guillaume S, Jaussent I, Bellivier F, Leboyer M Castelnau D et al (2007). Psychiatric diagnoses and personality traits associated with disadvantageous decision-making. Eur Psychiatry 22: 455-461.
30. Kelley BJ, Duker AP, Chiu P (2012). Dopamine agonists and pathologic behaviors. Parkinsons Dis 2012: 603631.
31. Kimberg DY, D'Esposito M, Farah MJ (1997). Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 8: 3581-3585.
32. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE (2005). Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11: 381-386.
33. Kvernmo T, Hartter S, Burger E (2006). A review of the receptorbinding and pharmacokinetic properties of dopamine agonists. Clin Ther 28: 1065-1078.
34. Lader M (2008). Antiparkinsonian medication and pathological gambling. CNS Drugs 22: 407-416.
35. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM Mendez MF (2010). Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 22: 8-18.
36. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ (2009). The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebocontrolled studies. Clin Ther 31: 89-98.
37. Madden GJ, Johnson PS, Brewer AT, Pinkston JW, Fowler SC (2010). Effects of pramipexole on impulsive choice in male wistar rats. Exp Clin Psychopharmacol 18: 267-276.
38. Martino DJ, Strejilevich SA, Torralva T, Manes F (2011). Decision making in euthymic bipolar I and bipolar II disorders. Psychol Med 41: 1319-1327.
39. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R et al (2000). Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12: 268-275.
40. McKeon A, Josephs KA, Klos KJ, Hecksel K, Bower JH, Michael BJ et al (2007). Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 13: 516-519.
41. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD Robbins TW (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20: RC65.
42. Mierau J, Schneider FJ, Ensinger HA et al (1995). Pramipexole binding and activation of cloned and expressed dopamine D2 D3 and D4 receptors. Eur J Pharmacol 290: 29-36.
43. Munhoz RP, Fabiani G, Becker N, Teive HA (2009). Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report. J Sex Med 6: 1177-1180.
44. Piercey MF (1998). Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 21: 141-151.
45. Pizzagalli DA, Goetz E, Ostacher M, Iosifescu DV, Perlis RH (2008). Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. Biol Psychiatry 64: 162-168.
46. Pontone G, Williams JR, Bassett SS, Marsh L (2006). Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67: 1258-1261.
47. Potenza MN, Voon V, Weintraub D (2007). Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 3: 664-672.
48. Riba J, Kramer UM, Heldmann M, Richter S, Munte TF (2008). Dopamine agonist increases risk taking but blunts rewardrelated brain activity. PLoS One 3: e2479.
49. Schultz W (2006). Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 57: 87-115.
50. Strejilevich SA, Martino DJ, Igoa A, Manes F (2011). Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 23: E2-E3.
51. Takata K, Kitamura Y, Kakimura J, Kohno Y, Taniguchi T (2000). Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs talipexole and pramipexole. Brain Res 872: 236-241.
52. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE Strafella AP (2009). Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34: 2758-2766.
53. van Holstein M, Aarts E, van der Schaaf ME, Geurts DE, Verkes RJ Franke B et al (2011). Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology (Berl) 218: 567-78.
54. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S et al (2006a). Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67: 1254-1257.
55. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M Fox S et al (2006b). Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66: 1750-1752.
56. Waters-Wood SM, Xiao L, Denburg NL, Hernandez M, Bechara A (2012). Failure to learn from repeated mistakes: persistent decision-making impairment as measured by the iowa gambling task in patients with ventromedial prefrontal cortex lesions. J Int Neuropsychol Soc 18: 927-930.
57. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M Voon V et al (2010). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67: 589-595.
58. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH Duda JE et al (2006). Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63: 969-973.
59. Ye Z, Hammer A, Camara E, Munte TF (2011). Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp 32: 800-811.
60. Yechiam E, Hayden EP, Bodkins M, O'Donnell BF, Hetrick WP (2008). Decision making in bipolar disorder: a cognitive modeling approach. Psychiatry Res 161: 142-152.
61. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al (2004). Pramipexole for bipolar II depression: a placebocontrolled proof of concept study. Biol Psychiatry 56: 54-60.